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A major portion of the mammalian genome is transcribed to produce large numbers of noncoding RNAs (ncRNAs). During the 
past decade, the discovery of small RNAs, including the microRNAs (miRNA) and small interfering RNAs (siRNA), has led to 
important advances in biology. The breadth of the ncRNA field of study has substantially expanded and many recent results have 
revealed a range of functions that can be attributed to the miRNAs and other ncRNAs. For example, H19 RNA, HOTAIR RNA, 
transcribed ultraconserved regions (T-UCRs), natural antisense RNA, transfer RNA and mitochondrial noncoding RNA have been 
suggested to play important roles in cancers and other diseases as well as in diverse cellular processes. In this review, we focus on 
the current status of several classes of ncRNAs associated with cancer with the emphasis on those that are not microRNAs. 
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Mounting evidence has revealed that a major portion of the 
mammalian genome is transcribed to produce large numbers 
of noncoding RNAs (ncRNAs), that is, RNAs that either do 
not have an open reading frame or RNAs that have a short 
poorly conserved open reading frame and do not code for a 
protein [1,2]. During the past decade, the discovery of small 
RNAs including the microRNAs (miRNAs) and small in-
terfering RNAs (siRNAs) has led to major advances in bi-
ology. After miRNAs were first connected to cancer patho-
genesis [3], accumulating data have pointed to a central 
regulatory role for miRNAs in the initiation and progression 
of most of the cancers that have been analyzed so far. Re-
cently, the breadth of the ncRNA field of study has substan-
tially expanded. A series of studies have revealed the essen-
tial roles of many ncRNAs in diverse cellular processes 
including cancer; these ncRNAs include H19 RNA, HOTAIR 
RNA, transcribed ultraconserved regions (T-UCRs), natural 
antisense RNA, transfer RNA and mitochondrial noncoding 
RNA (Figure 1). In this review, we focus on the current 
status of the research into the several classes of ncRNAs 
associated with cancer. 
1  MicroRNAs and cancer 
MicroRNAs (miRNAs), a category of small ncRNA mole-
cules with lengths of 18–25 nucleotides, were discovered 
recently. MiRNAs act as post-transcriptional regulators of 
genes by sequence-specific binding to the 3′ untranslated 
regions (3′ UTRs) of target mRNAs. Release 17 (April 2011) 
of the miRBase database (http://microrna.sanger.ac.uk/) cat-
alogues 1424 human miRNAs. Over 60% of human protein- 
coding genes have been suggested to be under selective 
pressure to maintain their pairing to miRNAs [4]. Depend-
ing on the degree of sequence complimentary between the 
miRNA and 3′ UTR, the pairing might result in inhibition of 
translation and/or degradation of the target mRNA [5,6]. 
Several miRNAs that previously were described as sup-
pressors have been found to be either deleted or mutated in 
various human malignancies. Calin et al. [3] first reported 
that miR-15a and miR-16-1, located in a cluster on chromo-
some 13q14, a frequently deleted region in B cell chronic  
960 Lin M, et al.   Chin Sci Bull   March (2012) Vol.57 No.9 
 
Figure 1  Summary of ncRNAs involved in tumorigenesis and cancer 
biology. The roles of each of the ncRNA are described in the correspond-
ing sections of the review. 
lymphocytic leukemia (CLL), could function as tumor sup-
pressor genes. This finding prompted the mapping of all 
miRNA genes to chromosomal locations. The mapping re-
vealed that a significant fraction of miRNAs mapped to 
cancer-associated genomic regions in human [7] and mouse 
[8], suggesting a connection between the deregulation of 
miRNAs and tumorigenesis accompanied by chromosomal 
aberrations such as deletions and amplifications. 
The loss of members of the let-7 family of miRNAs re-
sulted in the constitutive overexpression of the ras onco-
gene [9]. It was found that miR-15a and miR-16-1 target the 
BCL2 oncogene that inhibits apoptosis [3]. It is clear that 
the loss of the miRNAs could contribute to malignant trans-
formation through the dysfunction of cellular oncogenes. 
However, in various human tumors, the overexpression 
of miRNAs has been observed and the evidence indicated 
that some of these miRNAs could function as oncogenes. 
The two miRNAs that were first found to be overexpressed 
in cancers were the miR-155 and miR-17-92 clusters [10,11]. 
Interestingly, in solid cancers of epithelial origin and in 
leukemias and lymphomas, miR-155 was highly expressed 
and acted as an oncogene. However, in endocrine tumors it 
was significantly down-regulated and possibly had suppres-
sive functions [12]. These studies suggest that the roles of 
miRNAs in cancers are tissue and tumor specific. 
Various biological processes associated with cancer are 
regulated by microRNAs; they include transcription, cell- 
cycle regulation, apoptosis, angiogenesis, invasion and me-
tastasis [13]. Numerous miRNA-target gene pairs have been 
reported to be involved with tumorigenesis (for a review, 
see [14]). 
Because miRNA expression profiles reflect tumor origin, 
stage and other pathological variables, the profiles could be 
used as diagnostic or prognostic tools. Furthermore, in tu-
mors in which miRNAs are either lost or overexpressed, 
corresponding miRNAs or anti-miRNAs [15] might be con-
sidered as drugs that could induce apoptosis and/or cell cy-
cle arrest in cancer cells depending on their deregulation 
role for growth and survival. Here we have briefly reviewed 
the relationship between miRNAs and cancer; however, 
there are many reports and reviews that discuss this subject 
and readers are referred to the related references for more 
detailed information [16,17]. 
2  Roles of other noncoding RNAs in cancer 
While recent studies strongly support the role of microRNAs 
in the pathogenesis of the majority of cancers studied so far, 
recent investigations into the functions of other ncRNAs 
have indicated that they also play essential roles in the 
pathogenesis of cancers. These results add a new layer of 
complexity to the molecular architecture of human cancers. 
Here we briefly review several types of ncRNAs that drive 
cancer development and progression through different 
mechanisms in human cancers. 
2.1  Large intergenic noncoding RNAs (lincRNAs)  
There is growing recognition that mammalian cells produce 
many thousands of large intergenic transcripts [18]. To date, 
about a dozen functionally well-characterized large inter-
genic noncoding RNAs (lincRNAs) with transcript sizes 
ranging from 2.3 to 17.2 kilonucleotide (knt) have been 
reported in mammals [19,20]. These lincRNAs have distinc-
tive biological roles in diverse molecular mechanisms that 
include imprinting (e.g. H19 RNA), trans-acting gene regu-
lation (e.g. HOTAIR RNA), mediating global gene repres-
sion in the p53 response (e.g. lincRNA-p21), functioning in 
X-chromosome inactivation (e.g. Xist) [20] and regulating 
nuclear import (e.g. Nron) [21]. Recent studies suggest that 
some of the lincRNAs, for example H19 and HOTAIR, are 
involved in cancer progression and metastasis. 
(i) H19 RNA.  H19 is a maternally imprinted gene lo-
cated on chromosome 11p15.5. It transcribes into a spliced 
2.5-knt polyadenylated long ncRNA (H19 RNA). Postna-
tally, its expression is shut off in most tissues; it is reac-
tivated during adult tissue regeneration and tumorigenesis 
[22,23]. The imprinted cluster loci have been implicated in 
a variety of disorders and cancer predispositions for both 
pediatric and adult tumors. This observation implied that 
H19 was a potential tumor suppressor. Studies by Hao and 
Crenshaw [24] demonstrated that the induced expression of 
a transfected copy of H19 RNA suppressed cellular prolif-
eration and tumorigenesis in certain tumor cell lines. This 
further placed the H19 as a candidate gene with some kind 
of role in tumorigenesis. Later studies found that H19 expres-
sion was reduced or extinguished in a proportion of Wilms’ 
tumors and embryonal rhabdomyosarcoma [25,26]. These 
data show that H19 can act as a tumor suppressor gene. 
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Numerous reports have linked H19 expression and car-
cinogenesis, providing evidence for H19 as an oncogene 
[23,27] and recent studies have shown that altered H19 ex-
pression is associated with different stages of tumorigenesis, 
such as cell de-differentiation [28], blood vessel develop-
ment [29] and tumor metastasis [30]. 
Even though many related studies have identified H19 
RNA that are aberrantly expressed in cancers, how H19 
fulfills its tumor suppressing or oncogenic tasks remains 
poorly understood. Berteaux and Lottin [31] found that H19 
overexpression had a significant impact on breast cancer 
cell proliferation; H19 expression accelerated S-phase entry 
and cell cycle progression by controlling the direct and spe-
cific binding of transcription factor E2F1 to its promoter. A 
miRNA (miR-675) has recently been profiled in exon 1 of 
the human H19 genes, suggesting that H19 RNA may have 
two different functions: one as the spliced full-length tran-
script and the other as the miR-675 precursor [32]. This du-
ality could explain the conflicting functions (either as a 
growth suppressor or as a growth enhancer) that have been 
ascribed to H19 in the control of tumor growth. 
IGF-2 is an oncogene which was identified as an oppo-
sitely imprinted (paternally imprinted) gene to H19 in the 
same imprinting cluster [33]. H19 and IGF-2 have similar 
expression patterns in the same tissues at the same devel-
opmental stages during embryogenesis [34]. Losses of im-
printing of the IGF2 gene and inactivation of the H19 gene 
have been implicated in the pathogenesis of embryonal tu-
mors [35]. This pattern of gene expression suggests that 
these two genes may be co-regulated. In addition, H19 RNA 
was reported to be involved in the repression of the IGF-2 
oncogene by affecting either its transcription [36] or its 
translation [37]. 
Different research groups have reported several different 
elements that regulate H19 expression in tumors. Boutros et 
al. [23] identified c-Myc that directly binds to the H19 
promoter and sustantially up-regulates the transcription of 
the maternal H19 allele by recruiting histone acetyltransferase 
(HAT). Their results have further indicated that up-regula-     
tion of H19 by Myc contributes significantly to the tumor-
igenic phenotype of breast and lung cancer cells. In breast 
cancer, H19 was reported to be a target gene for hepatocyte 
growth factor (HGF) [38]. These results suggest the possi-
bility of using the H19 promoter in gene therapy to drive the 
expression of cytotoxic genes in tumorigenic cells [39]. 
(ii) HOTAIR.  Rinn and Kertesz [40] have characterized 
a 2158 nucleotide lincRNA, termed HOTAIR (for HOX an-
tisense intergenic RNA), and made the surprising discovery 
that this ncRNA acts in trans to regulate a HOX gene cluster 
on a completely different chromosome, not the HOX gene 
cluster that encodes the ncRNA itself. Mammalian homeo-
box (Hox) genes (HOXA–D), which establish the body plan 
during early development, are clustered at four chromoso-
mal loci. HOTAIR, which is transcribed from the HOX C 
locus, can target Polycomb repressive complex 2 (PRC2) 
and other chromatin regulators to the HOX D locus and po-
tentially many other genomic loci [40–42]. Rinn and Kertesz 
[40] have profiled expression patterns of the transcriptional 
landscape of these loci and identified ncRNAs correspond-
ing to chromatin regions with different epigenetic modifica-
tions, suggesting the mechanism might be epigenetic; how-
ever, this still remains an open question. Nevertheless, this 
is the first example of an RNA expressed on one chromo-
some influencing transcription on another chromosome. 
These findings reveal a new mechanism whereby ncRNAs 
can determine the silencing of distant chromosome regions 
that might have important implications for both disease and 
development. 
Recently, Gupta and Shah [41] reported that HOTAIR is 
systematically dysregulated in breast carcinoma and, nota-
bly, that HOTAIR regulates metastatic progression. They 
found that HOTAIR recruits the PRC2 complex to specific 
target genes genome-wide, leading to alteration of histone 
H3 lysine 27 methylation, epigenetic silencing of metastasis 
suppressor genes (such as JAM2, PCDH10 and PCDHB5), 
and inducing positive regulator genes of metastasis (such as 
ABL2, SNAIL, and laminins). HOTAIR-altered gene expres-
sion was reversed after PRC2 depletion. 
The interdependence between HOTAIR and PRC2 may 
indicate potential therapeutic applications. Tumors that are 
sensitive to inhibitors of PRC2 could be identified by mon-
itoring the increased level of HOTAIR [43]. Conversely, 
suppression of endogenous HOTAIR or inhibition of the 
HOTAIR-PRC2 interaction may provide potential therapeu-
tic targets to tumors that overexpress Polycomb proteins.  
(iii) LincRNA-p21.  In investigations into the potential 
biological roles of lincRNAs, several lincRNAs were iden-
tified to be regulated by p53. Huarte et al. [44] have demon-
strated that numerous lincRNAs are important components 
in the p53-dependent transcriptional pathway. Of these, lin-
cRNA-p21 functions as a direct p53 transcriptional target in 
response to DNA damage; it is required for p53-dependent 
apoptotic responses to DNA damage. LincRNA-p21 acts by 
modulating nuclear ribonucleoprotein K (hnRNP-K) locali-
zation through its interaction with hnRNP-K. 
Various hypothetical mechanisms by which lincRNA- 
p21 could contribute to repression at specific loci have been 
suggested. They include: (1) lincRNA-p21 might direct a 
protein complex to specific loci by Crick-Watson base pair-
ing; (2) lincRNA-p21 might act by forming DNA-DNA- 
RNA triple-helical structures; or (3) lincRNA-p21 might 
alter the binding specificity of DNA-binding proteins to 
influence their target preference. The precise mechanism 
needs further confirmation. 
Because p53 is a well-known tumor suppressor gene, it is 
clear that lincRNA-p21 and several other lincRNAs function 
in an important pathway for cancer. It is tempting to specu-
late that other lincRNAs may also play important roles in 
numerous other tumor suppressor or oncogenic pathways, 
suggesting that the lincRNAs represent an unknown para-
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digm in cellular transformation and metastasis. It is im-
portant to determine whether lincRNA genes can serve as 
tumor suppressor genes or oncogenes in future studies. 
2.2  Transcribed ultraconserved regions (T-UCRs) 
Evolutionarily conserved sequences within or adjoining 
orthologous genes often serve as critical cis-regulatory re-
gions. Recent studies have identified long, noncoding ge-
nomic regions that are perfectly conserved in human, mouse 
and rat genomes; these regions are termed ultra-conserved 
regions (UCRs). UCRs represent a group of sequences 200– 
779 bp in length that were first discovered by Bejerano in 
2004 [45,46]. UCRs are frequently located at fragile sites 
and genomic regions involved in cancers. A large fraction 
of the genomic UCRs encode a particular set of ncRNAs 
called transcribed ultraconserved regions (T-UCRs) that 
exhibit altered expression in human cancers [47]. 
Calin et al. [47] demonstrated that a new class of UCRs 
was significantly altered at both the DNA and RNA levels 
in adult chronic lymphocytic leukemias (CLL), colorectal 
and hepatocellular carcinomas. In colon cancer, uc.73A, one 
of the most statistically up-regulated transcribed-UCRs (T- 
UCRs), was found to induce cell proliferation by reducing 
apoptosis, suggesting its function as an oncogene. 
Scaruffi et al. [48] suggested that deregulation of the mi-
croRNA/T-UCR network may play an important role in the 
pathogenesis of neuroblastoma and tumor-associated T-UCRs 
in CLL were found to be regulated by certain miRNAs [47]. 
These results led to the hypothesis that T-UCRs along with 
miRNAs may define signatures associated with the diagno-
sis, prognosis and treatment of tumors. The roles of T-UCRs 
in cancer cells remain to be defined. 
2.3  Natural antisense RNA 
Natural antisense transcripts (NATs), also called antisense 
RNAs, are a group of RNAs that contain sequences that are 
complementary to other endogenous transcripts. Both sense 
and antisense RNAs can either encode proteins or be 
noncoding transcripts; however, the most prominent product 
of antisense transcription in the mammalian genome is a 
noncoding antisense RNA partner of a protein-coding tran-
script [49]. To date, numerous NATs with repressive func-
tions have been described in different organisms. They can 
be transcribed in cis from opposing DNA strands at the 
same genomic loci (cis-NATs), or in trans from separate 
loci (trans-NATs). Most of the studies in the past few years 
have focused on cis-NATs. 
Earlier studies identified a certain numbers of sense-anti-     
sense transcripts exhibing interactions that were associated 
with cancer. For example, Bcl-2 antisense RNA IgH dereg-
ulates Bcl-2 gene expression in human follicular lymphoma 
cell lines [50] and the NAT of EPR-1 (effecter cell protease 
receptor-1) down-regulates survivin expression, thus, func-
tioning as an inhibitor of apoptosis in a human colon cancer 
cell line [51]. Although many NATs have been identified 
recently, our understanding of how antisense transcripts 
regulate gene expression in human cells remains mostly 
incomplete. Recent functional validation investigations have 
indicated that antisense transcripts are not a uniform group 
of regulatory RNAs but instead belong to multiple catego-
ries that have some common features. Pioneering studies in 
several eukaryotic systems have identified a number of 
proposed mechanisms for the antisense-mediated regulation 
of sense mRNA gene expression [52]. The proposed mech-
anisms have been categorized into four main groups: mecha-
nisms related to transcription, RNA-DNA interactions (such 
as genomic imprinting, alteration of DNA methylation and 
chromatin modification), nuclear RNA duplex formation, 
and cytoplasmic RNA duplex formation (such as the for-
mation of endogenous siRNAs and masking miRNA-binding 
sites). For a review of these mechanisms, see [53]. 
The growing list of validated sense-antisense transcript 
pairs includes many important developmental genes as well 
as genes known to be involved in various human disorders, 
including cancer. It is well known that suppression of tran-
scription is usually brought about by DNA and chromatin 
modification at the promoter region of the sense strand. 
Previous studies have reported a few examples of antisense 
transcripts that are implicated in cancer via their role in al-
tering DNA and chromatin modification. p15 is a well- 
documented tumor suppressor gene that is frequently genet-
ically deleted or epigenetically silenced in a wide variety of 
tumors including leukemia, melanomas, gliomas and lung 
cancers. Recently, Yu et al. [54] identified a p15 antisense 
RNA (p15AS RNA), which can induce epigenetic silencing 
of p15. This study demonstrated that the antisense RNA 
could silence its sense gene at the transcriptional level by 
affecting DNA methylation and histone modifications. This 
result was confirmed by Morris [55] who found that p21AS 
RNA directed the trimethylation of histone H3 at lysine 27 
(H3K27me3) in the p21 sense promoter region, resulting in 
the suppression of p21 gene expression. In addition, p53 as 
a tumor suppressor gene plays an important role in the pre-
vention of human cancer and its mutations result in human 
tumors. Recent studies have revealed that Wrap53, a natural 
antisense transcript of p53, plays an important role in the 
regulation of p53 mRNA and in the induction of the p53 
protein by targeting the 5′ UTR of p53 mRNA. Unlike the 
p15 and p21 antisense RNAs, Wrap53 antisense and p53 are 
co-expressed in cells [56]. 
NATs associated with genomic imprinting were identi-
fied in several reports. A region on chromosome 6 that con-
tains three maternally imprinted protein-coding genes (Igf2r, 
Slc22a2 and Slc22a3) has been shown to be controlled by a 
paternally expressed noncoding antisense Igf2r RNA (Air) 
[57]. Air is a 108-kb unspliced and repeat-rich transcript 
which only overlaps in an antisense orientation with Igf2r 
and not with Slc22a2 or Slc22a3 [58]. However, the expres-
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sion of Air can silence all three protein-coding genes in the 
imprinted cluster [59]. 
Significantly, the development of tools to identify anti-
sense transcripts that are associated with cancer loci should 
provide a better insight into the functions of different anti-
sense transcripts and the molecular etiology associated with 
many important human cancers. Moreover, the ability of 
NATs to regulate the expression of sense transcripts could 
provide numerous new potential drug targets in the emerg-
ing field of functional antisense transcripts. 
2.4  Transfer RNA 
The increased expression of RNA polymerase (pol) III 
transcription factors and of pol III products (such as tRNA 
and 5S rRNA) has often been observed in transformed and 
tumor cells in, for example, ovarian and cervical carcinomas 
and breast cancer [60–62]. However, whether pol III is a 
causative factor in cancer is unclear because recurrent mu-
tations in pol III subunits or the associated transcription 
factors have not been found in tumors. 
tRNAs are one large class of pol III noncoding tran-
scripts. Earlier research showed that the tRNA methyltrans-
ferase Misu was overexpressed in breast and colon cancers, 
and that Misu RNAi (RNA interference) inhibited growth of 
carcinomas [63], supporting the conclusion that tRNA me-
tabolism can have a strong influence on oncogenic trans-
formation. 
Recently, White et al. [64] reported that elevated tRNA 
production can have a causal role in oncogenic transfor-
mation. They demonstrated that the phenotypic effects of 
pol III transcription factor Brf1 induction was mimicked by 
elevated levels of a pol III product tRNAi
Met, the initiator 
tRNAMet. Moreover, a modest overexpression of tRNAi
Met 
was found to significantly stimulate translation, suggesting 
the activation of tRNA expression that was often observed 
in transformed cells might have functional consequences for 
the development of cancer [64]. White et al. created stably 
transfected lines of immortalized mouse embryonic fibro-
blasts carrying cDNA encoding tRNAMet that expressed 
elevate levels of cyclin D1 and c-Myc proteins without cor-
responding changes in the levels of their mRNA. Mei et al. 
[65] microinjected tRNA into cells and found that this led to 
significant inhibition of cytochrome c-induced apoptosis. 
Therefore, the tRNA levels in cells may be relevant for the 
translation of the important genes required for the tumor-
igenic process and may play a central role in cancer devel-
opment and progression. The precise mechanism and possi-
ble therapeutic applications of tRNA in cancer need to be 
explored further. 
2.5  Noncoding mitochondrial RNAs 
The mammalian mitochondrial genome is a double-stranded 
circular DNA about 16500 nucleotides long [66]. It encodes 
the 12S and 16S ribosomal RNAs, 22 tRNAs and 13 poly-
peptides [67]. Besides these coding regions, the mitochondrial 
DNA (mtDNA) contains an approximately 1-kb noncoding 
region called the D-loop region that contains the origin of 
H-strand replication and the promoters for transcription of 
the H-strand and L-strand templates [68]. 
Several models that link mitochondrial dysfunction to 
cancer have been proposed. However, only a few of these 
models discuss the role of noncoding mitochondrial RNA 
(ncmtRNA) in cancer, and the precise mechanism of their 
involvement is yet to be defined. 
mtDNA mutations have been linked to a broad spectrum 
of malignancies. Mutations have been described in both 
rRNAs, in all 22 tRNAs, in all 13 of the mtDNA-encoded 
subunits of the respiratory chain complexes and in the mi-
tochondrial D-loop regions [69]. Interestingly, about half of 
the disease-related mutations (237 in total 480) are located 
within the ncmtRNA genes (see http://www.mitomap.org/ 
MITOMAP) and, given that these sequences comprise only 
10% of the mitochondrial genome, this result indicates a 
possible role for the ncmtRNAs in various diseases includ-
ing cancer [70]. 
Mei et al. [65] have reported that when mitochondrial 
tRNAs along with cytosolic tRNAs bind to cytochrome c 
they impair the interaction of cytochrome c with Apaf-1, a 
caspase activator, and prevent the formation of the apopto-
some. This finding raised the possibility that mitochondrial 
tRNAs may play a role in determining cellular responsive-
ness to apoptotic stimuli. 
In mouse cells, Villegas et al. [71,72] identified the 
presence of a mitochondrial RNA (mtRNA) that contained 
an inverted repeat (IR) of 121 nucleotides that covalently 
linked to the 5′ end of the mitochondrial 16S RNA. Later 
the same workers demonstrated that human cells contain a 
transcript of 2374 nt with similar structural features to the 
mouse mtRNA. This transcript contained a stem-loop 
structure with an 820-bp double-stranded region and a 40-nt 
loop, and that it was expressed in human proliferating cells 
but not in resting cells, suggesting that this ncmtRNA may 
play a role in cell proliferation [73]. Recently, Burzio et al. 
[74] reported that in addition to this transcript, normal hu-
man proliferating cells in culture expressed two ncmtRNA 
transcripts, sense ncmtRNA (SncmtRNA) and antisense 
ncmtRNA (ASncmtRNA). The expression of SncmtRNA 
and the down-regulation of the ASncmtRNAs was observed 
in 15 different tumor cell lines and in tumor cells present in 
273 cancer biopsies corresponding to 17 different cancer 
types. The correlation of SncmtRNA and the replicative 
state of the cells suggests that SncmtRNA may play a role 
in regulating cell cycles. However, how this molecule might 
participate in the regulation of cell cycles remains unknown. 
Our understanding of ASncmtRNAs is even lower; the 
down-regulation of ASncmtRNAs in tumor cells suggests 
its possible role as a unique mitochondria-encoded tumor 
suppressor [74]. 
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2.6  Other ncRNAs 
Many other ncRNAs including Alu RNA [75], Y RNA [76], 
and small nucleolar RNA [77], show abnormal expression 
patterns in cancerous tissues. Their roles and possible 
mechanisms are not reviewed here; however, some details 
about them are described in the references. 
3  Conclusion 
An understanding of ncRNA is crucial to the early detection 
and better diagnosis of cancer, for a more accurate descrip-
tion of the tumor type, and for a more effective therapy. 
Potentially, an attractive model of cancer treatments is ei-
ther to activate tumor-suppressor genes or to silence onco-
genes by programming specific noncoding RNAs. 
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